Certificate of Analysis



Product:

DOAC-Remove 20 (A) or 50 (B) or 250 (C) tablets

Art. No.:

5D-82410A/B/C-RUO

Lot:

434108

Expiration Date:

2030-01-31

Description:

DOAC-REMOVE™ tablets are intended to be used for removal of Direct Oral Anticoagulant (DOAC) compounds from human citrated plasma samples, including dabigatran, rivaroxaban, apixaban and edoxaban.

There is no significant effect on clotting factors.

FOR IN VITRO USE ONLY. FOR RESEARCH USE ONLY.

NOT FOR USE IN DIAGNOSTIC PROCEDURES.

Presentation:

20 (A), 50 (B) or 250 (C) tablets in a vial. Ready to use. Contains activated

carbon, specially formulated with additives.

Specification

Storage:

Store in a dry place at ambient (15-30°C) in its original packaging.

Analytical Data:

	Specification	itesaits
Weight (n=100):	18 - 22 mg/tablet	pass
Rivaroxaban binding:	≥ 1200 ng/mL	pass
Apixaban binding:	≥ 1000 ng/mL	pass
Edoxaban binding:	≥ 1000 ng/mL	pass
Dabigatran binding:	≥ 1200 ng/mL	pass

2025-02-10

Signed,

Results

5-Diagnostics AG Heuberg 7 CH-4051 Basel, Switzerland ordering@5-diagnostics.com | www.5-diagnostics.com Tel: +41-61-588 0784 | Fax: +41-61-588 0786